Elevidys Side Effects: What Every Parent Needs to Know

If your child is being considered for Elevidys (Delandistrogene Moxeparvovec-rokl), understanding the potential side effects is one of the most important steps in your decision-making process. Elevidys is a powerful one-time gene therapy for Duchenne muscular dystrophy (DMD), and like all gene therapies, it comes with both common and serious risks that require close monitoring.

This guide covers every side effect reported in clinical trials and post-market surveillance, explains which symptoms are normal versus concerning, and tells you exactly when to contact your child's medical team.

What Is Elevidys?

Elevidys is a gene therapy made by Sarepta Therapeutics that delivers a shortened form of the dystrophin protein (called micro-dystrophin) to muscle cells using an AAVrh74 viral vector. It's approved for ambulatory DMD patients aged 4 and older with a confirmed DMD gene mutation amenable to treatment.

Elevidys is administered as a single one-time intravenous infusion at a specialized treatment center. Patients must take corticosteroids starting the day before infusion and continuing for at least 60 days after. For more details about the treatment, read our guide on what Elevidys is and how it's used.

Common Side Effects

The following side effects were reported in clinical trials and are considered relatively common after Elevidys infusion:

• Vomiting — One of the most frequently reported side effects. This may occur during or shortly after infusion and can usually be managed with anti-nausea medication.
• Nausea — Often accompanies vomiting and typically resolves within the first few days after treatment.
• Liver enzyme elevation (elevated transaminases) — Nearly all patients experience some rise in liver enzymes (ALT and AST) after Elevidys infusion. This is monitored closely through regular blood tests. Mild elevations are expected, but significant rises require immediate attention.
• Fever (pyrexia) — A low-grade fever in the days following infusion is common and reflects the body's immune response to the viral vector.
• Low platelet count (thrombocytopenia) — Some patients develop temporarily reduced platelet counts, which are monitored through blood work.
• Elevated Troponin-I — This cardiac marker can rise after infusion, indicating mild cardiac stress. It is monitored as part of routine post-infusion lab work.

Most of these common side effects occur within the first few weeks after infusion and resolve with supportive care and the prescribed corticosteroid regimen.

Serious Side Effects

Elevidys carries a Boxed Warning — the most serious safety warning the FDA can require — for the risk of liver injury. The following serious side effects have been reported:

• Acute liver failure (including fatal cases) — This is the most serious risk associated with Elevidys. Reports of fatal acute liver failure led the FDA to add a Boxed Warning and restrict the indication to ambulatory patients only. Symptoms include yellowing of the skin or eyes (jaundice), dark urine, severe fatigue, loss of appetite, abdominal pain, and confusion.
• Acute serious liver injury — Even without full liver failure, significant liver damage can occur. This is why frequent liver function testing is mandatory after infusion.
• Mesenteric vein thrombosis — Blood clots in the veins that drain the intestines. Symptoms include severe abdominal pain, bloating, nausea, and bloody stools.
• Bowel ischemia and necrosis — Reduced blood flow to the intestines that can lead to tissue death. This is a medical emergency requiring immediate treatment.
• Portal hypertension — High blood pressure in the portal vein system, which carries blood from the digestive organs to the liver.
• Acute serious myocarditis — Inflammation of the heart muscle. Symptoms include chest pain, shortness of breath, rapid or irregular heartbeat, and fatigue.
• Thrombotic microangiopathy — A condition involving small blood clots in tiny blood vessels throughout the body, which can affect kidney function and other organs.
• Serious infections — Because patients must take corticosteroids and possibly other immunosuppressants after infusion, their immune systems are suppressed. This increases the risk of potentially life-threatening infections.
• Immune-mediated myositis — The body's immune system may attack muscle tissue in response to the viral vector or the micro-dystrophin protein.

Specific Populations and Special Considerations

Certain groups face higher risks with Elevidys:

• Non-ambulatory patients — Elevidys is no longer approved for non-ambulatory DMD patients following reports of fatal liver injury in this population. The indication was restricted in late 2025.
• Patients with preexisting liver impairment — Elevidys is contraindicated in patients with liver problems, as the risk of fatal liver injury is too high.
• Patients with recent vaccinations — Live vaccines should be avoided due to the immunosuppressive regimen required after Elevidys.
• Patients with active infections — Treatment should be delayed until infections are fully resolved.
• Patients with DMD gene deletions affecting exons 8 or 9 — These patients are specifically excluded from treatment because the micro-dystrophin construct does not address their mutation type.

How to Manage Side Effects

Your child's treatment team will have a detailed monitoring plan, but here are some general guidelines:

For Common Side Effects

• Vomiting and nausea — Anti-nausea medications may be prescribed. Keep your child hydrated with small, frequent sips of water or electrolyte drinks.
• Fever — Your doctor may recommend acetaminophen (Tylenol). Do not give aspirin or NSAIDs without checking with your doctor, as these could interact with other medications or affect platelet counts.
• Fatigue — Rest is important in the weeks after infusion. Don't push your child to resume normal activity levels too quickly.

For Monitoring and Lab Work

• Attend every scheduled lab appointment. Liver function, platelet counts, and cardiac markers are checked frequently — often weekly in the first months.
• Keep a symptom diary noting any changes in your child's appetite, energy, urine color, skin color, or behavior.
• Make sure your child takes the prescribed corticosteroids exactly as directed. Do not stop them early, even if your child seems fine.

When to Call Your Doctor Immediately

Contact your child's medical team right away if you notice any of these warning signs:

• Yellowing of the skin or whites of the eyes (jaundice)
• Dark or tea-colored urine
• Severe abdominal pain or swelling
• Unusual bleeding or bruising
• Severe or persistent vomiting
• Chest pain or rapid heartbeat
• High fever (over 101°F) or signs of infection
• Confusion, extreme drowsiness, or difficulty waking up
• Bloody stools
• Difficulty breathing

If your child shows signs of jaundice, extreme fatigue, or confusion, go to the emergency room immediately. These could be signs of acute liver failure, which requires urgent medical intervention.

Final Thoughts

Elevidys is a potentially life-changing treatment for children with DMD, but it carries significant risks that require careful monitoring and quick action if problems arise. Understanding the full range of side effects — from common reactions like nausea and fever to serious complications like liver failure — helps you stay prepared and advocate for your child's safety.

Talk to your child's neuromuscular specialist about creating a detailed monitoring plan before infusion day. For more information about Elevidys, read our guides on how Elevidys works, drug interactions to watch for, and how to find a prescribing doctor.

If you need help locating Elevidys or navigating the treatment process, visit Medfinder.